Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

NCT03004833 is registered in ClinicalTrials.gov with University of Cologne as lead sponsor.

NCT NCT03004833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03004833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
Lead sponsor
University of Cologne
Phase
Phase 2
Overall status
Completed
Start date
February 21, 2017
Completion date
August 22, 2022
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

classical hodgkin lymphoma